From Hits to Leads: How AI is Accelerating Drug Discovery for Pharma
From hits to leads, AI is revolutionizing drug discovery. Traditional screening methods can be slow, costly, and inefficient, but with AI-driven virtual screening and advanced analytics, pharma companies can rapidly identify promising compounds, optimize leads, and fast-track life-saving treatments. Discover how Agilisium’s AI solutions are transforming drug discovery.
Early-stage drug discovery is a complex process that involves identifying promising compounds (hits) with activity against a target, then optimizing their pharmacological properties over multiple iterations to develop potential leads for preclinical studies. However, traditional drug discovery methods—systematic compound analysis, molecular modifications, and serendipitous findings—are often slow, costly, and inefficient. As molecular libraries expand and development costs rise, the need for more effective screening approaches has become critical.
To accelerate this process, drug developers are turning to high-throughput screening, virtual screening, and AI-driven methodologies to identify leads with a higher likelihood of success. At Agilisium, we leverage advanced analytics and Generative AI to enhance the screening phase, helping researchers rapidly analyze vast molecular libraries with greater accuracy and cost efficiency. With deep learning, predictive analytics and natural language processing, we empower pharma companies to make data-driven decisions—fast-tracking the most promising candidates into preclinical development and ultimately bringing life-saving therapies to market sooner.
High-Throughput Screening: Pros, Cons, and Its Role in Drug Discovery
The adoption of high-throughput and ultra-high throughput screening (HTS and UHTS) of large physical libraries of molecules, which can include hundreds of thousands of structures from combinatorial chemistry, genomics, protein, and peptide libraries, has increased the speed of the process compared with previous methods. There are disadvantages, however – the costs for assays, reagents, staff, robotic systems and other equipment, along with the time required, can make HTS and UHTS prohibitively expensive. It can also produce a high rate of false positives, resulting in researchers spending time and money evaluating hits that don’t have the potential to become useful leads for drug development.
Evolving Drug Discovery: From High-Throughput to Virtual Screening
Virtual screening has provided a step forward in efficiency. Virtual libraries can contain millions or billions of molecules or molecule fragments, and may include additional information such as 3D conformation, molecular weight, hydrophobicity and binding affinities. The virtual screening workflow filters the library, retaining the compounds that have the desirable characteristics, based on either their similarity with active compounds (ligand-based) or complementarity with target binding sites (receptor-, target- or structure-based). Virtual screening can process thousands of virtual molecules in a few hours, selecting potential hits that can then be optimized, synthesized and tested, and then further optimized. The leads can be validated in silico, in vitro and in vivo.
While virtual screening has advantages over HTS, including lower equipment and reagent costs, less impact on staff time, and greater speed, it does also have disadvantages:
- Ligand-based screening – similar compounds may not always have similar activity
- Receptor-based screening – accuracy depends on the understanding of ligand-target interaction
- Not all virtual molecules are biologically relevant or are able to be synthesized in the real world
- There may be issues with the algorithms used
- The quality of the hits produced depends on the quality or ‘developability’ of the molecules in the library
- The computational costs can be high
AI-Driven Screening: Advancing Drug Discovery
Researchers and drug developers today have access to an unprecedented volume of data—from virtual compound libraries to structured and unstructured datasets, including electronic health records, scientific literature, genomic and proteomic data, and preclinical and clinical trial results. While this wealth of information is invaluable, efficiently analysing and extracting meaningful insights remains a challenge. This is where advanced analytics, powered by AI-driven technologies, play a vital role.
In drug discovery, one of the first applications of advanced analytics is target identification and validation. Whether discovering new targets or repurposing existing ones for new diseases, machine learning algorithms can cross-reference multiomics data, biological networks, disease databases, and protein-protein interactions to uncover potential therapeutic opportunities. Our Insights Generation Agent streamlines this process by integrating diverse life sciences datasets, identifying patterns, detecting anomalies, and delivering actionable insights.
Once a target is selected, AI-driven high-throughput virtual screening (HTVS) enhances both ligand- and structure-based screening. In ligand-based virtual screening (LBVS), advanced analytics predict biological activity, physicochemical properties, and ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiles of compounds. In structure-based virtual screening (SBVS), AI models assess drug-target interactions to identify the most promising candidates. Our Observability Agent ensures end-to-end data integrity and anomaly detection, providing researchers with reliable insights across datasets. Meanwhile, our NexGen DLS Agent helps drug discovery teams uncover relationships between molecules and disease processes, accelerating lead identification.
Ensuring data accuracy and meaningful insights is key to making informed decisions in drug discovery. But equally important is how this information is managed, communicated, and acted upon across research teams. Seamless collaboration is essential for translating these insights into action. Our Content Generation Agent, purpose built for life sciences, ensures compliant data management and real-time insights sharing, enabling research teams to make informed decisions and streamline workflows with confidence.
AI’s Impact - Transforming the Journey from Lab to Life
With the growing complexity of drug development, pharma companies are constantly looking for ways to speed up innovation while managing costs and risks. AI-driven virtual screening and advanced analytics are changing the game—helping researchers quickly identify promising compounds, optimize leads, and improve the chances of success in clinical trials.
At Agilisium, we’re committed to supporting life sciences companies with cutting-edge AI solutions that simplify research and accelerate drug discovery. By making the process smarter and more efficient, we’re helping bring breakthrough treatments to patients faster
%20(1).png)
.avif)
%20(5).avif)
.avif)
